Advertisement
Australia markets closed
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • AUD/USD

    0.6515
    -0.0003 (-0.05%)
     
  • OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD

    2,254.80
    +16.40 (+0.73%)
     
  • Bitcoin AUD

    108,605.95
    +1,473.72 (+1.38%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • AUD/EUR

    0.6038
    +0.0004 (+0.06%)
     
  • AUD/NZD

    1.0905
    +0.0003 (+0.02%)
     
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NASDAQ

    18,254.69
    -26.15 (-0.14%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • Dow Jones

    39,807.37
    +47.29 (+0.12%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,384.42
    +216.35 (+0.54%)
     

Global Contrast Enhanced Ultrasound Market (2021 to 2028) - Size, Share & Trends Analysis Report

Dublin, Sept. 22, 2021 (GLOBE NEWSWIRE) -- The "Global Contrast Enhanced Ultrasound Market Size, Share & Trends Analysis Report by Product (Equipment, Contrast Agents), by Type (Non-targeted, Targeted), by End-use (Hospitals, Clinics), by Region, and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

The global contrast enhanced ultrasound market size is estimated to reach USD 2.71 billion by 2028, expanding at a CAGR of 4.0%. Introduction of affordable dyes, increasing sonography procedural volume, and contrast imaging modes becoming an integral feature of ultrasound systems are the prominent factors driving the market.

The increasing prevalence of cardiovascular diseases, liver lesions, renal lesions, gastrointestinal diseases, and vascular diseases globally is anticipated to boost the market growth, as these are major areas of clinical application of Contrast-enhanced Ultrasound (CEUS) systems.

The presence of several potential benefits in CEUS such as being completely radiation-free, quick, cost-efficient, and patient-friendly, in comparison to the contrast-enhanced CT/MRI, is expected to propel the growth of the market.

Increasing approvals of CEUS by regulatory bodies for new indications are expected to propel the growth of the market during the forecast period. For instance, the ultrasound dyes which were originally indicated for cardiac imaging have received an extension of indication for pediatric and liver imaging in several countries.

Contrast Enhanced Ultrasound Market Report Highlights

  • Based on product, the equipment segment held the largest revenue share in 2019. This can be attributed to the largest installed base of sonography technology compatible with CEUS

  • The contrast agents segment is expected to grow at the fastest rate of 4.0% during the forecast period owing to its approval of usage in the liver and pediatric imaging by the FDA

  • Based on type, the non-targeted segment held the largest revenue share in 2019 as most of the commercially available dyes are non-targeted agents

  • Numerous clinical trials conducted to determine the potential of diagnostic and therapeutic application of targeted imaging dyes in cancer care are expected to drive the segment during the forecast period

  • The hospitals segment held the largest market share in 2019 owing to the increasing number of emergency visits with medical conditions such as abdominal pain, abdominal/thoracic trauma, and cardiac complications

  • The clinics segment is anticipated to witness lucrative growth over the forecast period owing to the realization of economic and patient care benefits with the adoption of sonography devices in practice among physicians at primary and secondary care

  • In Asia Pacific, the market is expected to grow at the fastest rate owing to the limited accessibility to advanced CT/MRI imaging modalities such as CT and MRI, and the growing burden of cardiovascular disorders in China and India.

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Contrast Enhanced Ultrasound Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Reimbursement framework
3.4. Market Dynamics
3.4.1. Market driver analysis
3.4.1.1. Increasing prevalence of chronic illness diseases
3.4.1.2. Technological advancements
3.4.1.3. Extension of indication for use
3.4.2. Market restraint analysis
3.4.2.1. Low stability of contrast agents
3.4.2.2. Procedural complexity
3.4.2.3. Availability of alternatives
3.5. Contrast Enhanced Ultrasound Market Analysis Tools
3.5.1. Industry analysis - Porter's
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic landscape
3.5.3. Major deals & strategic alliances analysis
3.5.4. Market entry strategies
3.5.5. Covid-19 Impact Analysis

Chapter 4. Global Contrast Enhanced Ultrasound Market: Product Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. Equipment
4.1.2. Contrast Agent
4.2. Product Market Share, 2020 & 2028
4.3. Segment Dashboard
4.4. Global Contrast Enhanced Ultrasound Market by Product Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
4.5.1. Equipment
4.5.1.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
4.5.2. Contrast Agent
4.5.2.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)

Chapter 5. Global Contrast Enhanced Ultrasound Market: Type Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. Non-targeted
5.1.2. Targeted
5.2. Type Market Share, 2020 & 2028
5.3. Segment Dashboard
5.4. Global Contrast Enhanced Ultrasound Market by Type Outlook
5.5. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
5.5.1. Non-targeted
5.5.1.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
5.5.2. Targeted
5.5.2.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)

Chapter 6. Global Contrast Enhanced Ultrasound Market: End Use Estimates & Trend Analysis
6.1. Definitions and Scope
6.1.1. Hospitals
6.1.2. Clinics
6.1.3. Ambulatory Diagnostic Centers
6.2. End Use Market Share, 2020 & 2028
6.3. Segment Dashboard
6.4. Global Contrast Enhanced Ultrasound Market by End Use Outlook
6.5. Market Size & Forecasts and Trend Analyses, 2016 to 2028 for the following
6.5.1. Hospitals
6.5.1.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.5.2. Clinics
6.5.2.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)
6.5.3. Ambulatory Diagnostic Centers
6.5.3.1. Market estimates and forecast, 2016 - 2028 (Revenue, USD Million)

Chapter 7. Global Contrast Enhanced Ultrasound Market: Regional Estimates & Trend Analysis

Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competitive Categorization
8.2.1. Innovators
8.2.2. Market leaders
8.2.3. Emerging players
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2020
8.4. Public Companies
8.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
8.4.2. Company market share/ranking, by region
8.4.3. Competitive dashboard analysis
8.4.3.1. Market differentiators
8.4.3.2. Synergy analysis: major deals and strategic alliances
8.5. Private Companies
8.5.1. List of key emerging companies/technology disruptors/innovators
8.5.2. Funding outlook
8.5.3. Regional network map
8.5.4. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
8.5.5. Supplier ranking
8.5.6. Key company profiled
8.5.7. Lantheus Medical Imaging Inc.
8.5.7.1. Company overview
8.5.7.2. Financial performance
8.5.7.3. Product benchmarking
8.5.7.4. Strategic initiatives
8.5.8. Bracco Diagnostic Inc.
8.5.8.1. Company overview
8.5.8.2. Financial performance
8.5.8.3. Product benchmarking
8.5.8.4. Strategic initiatives
8.5.9. General Electric
8.5.9.1. Company overview
8.5.9.2. Financial performance
8.5.9.3. Product benchmarking
8.5.9.4. Strategic initiatives
8.5.10. Siemens Healthcare GmbH
8.5.10.1. Company overview
8.5.10.2. Financial performance
8.5.10.3. Product benchmarking
8.5.10.4. Strategic Initiative
8.5.11. nanoPET Pharma GmbH
8.5.11.1. Company overview
8.5.11.2. Financial performance
8.5.11.3. Product benchmarking
8.5.11.4. Strategic initiatives
8.5.12. ESAOTE SPA
8.5.12.1. Company overview
8.5.12.2. Financial performance
8.5.12.3. Product benchmarking
8.5.12.4. Strategic initiatives
8.5.13. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
8.5.13.1. Company overview
8.5.13.2. Financial performance
8.5.13.3. Product benchmarking
8.5.13.4. Strategic initiatives

For more information about this report visit https://www.researchandmarkets.com/r/axuu38

ADVERTISEMENT
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900